X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1418) 1418
life sciences & biomedicine (1336) 1336
humans (1302) 1302
ctla-4 antigen - antagonists & inhibitors (909) 909
immunotherapy (695) 695
animals (661) 661
oncology (578) 578
programmed cell death 1 receptor - antagonists & inhibitors (572) 572
immunology (484) 484
ctla-4 antigen - immunology (443) 443
antibodies, monoclonal - therapeutic use (411) 411
female (409) 409
mice (393) 393
cancer (390) 390
melanoma (365) 365
male (347) 347
ctla-4 protein (323) 323
immunotherapy - methods (318) 318
ctla-4 antigen (300) 300
lymphocytes (297) 297
b7-h1 antigen - antagonists & inhibitors (296) 296
ipilimumab (278) 278
lymphocytes t (269) 269
ctla-4 (258) 258
neoplasms - immunology (257) 257
melanoma - drug therapy (248) 248
programmed cell death 1 receptor - immunology (246) 246
t cells (246) 246
immune checkpoint (244) 244
tumors (235) 235
antineoplastic agents - therapeutic use (232) 232
care and treatment (217) 217
antigens (216) 216
treatment outcome (204) 204
middle aged (199) 199
t-lymphocytes - immunology (198) 198
cytotoxicity (184) 184
abatacept (174) 174
abridged index medicus (173) 173
melanoma - immunology (173) 173
neoplasms - drug therapy (172) 172
neoplasms - therapy (172) 172
immune system (169) 169
pd-1 (165) 165
metastasis (162) 162
antigens, cd (159) 159
antineoplastic agents, immunological - therapeutic use (159) 159
aged (157) 157
patients (154) 154
clinical trials (153) 153
mice, inbred c57bl (153) 153
antibodies, monoclonal - pharmacology (150) 150
ctla-4 antigen - metabolism (150) 150
adult (148) 148
antibodies, monoclonal - adverse effects (147) 147
pd-1 protein (145) 145
apoptosis (141) 141
immunoconjugates (138) 138
b7-h1 antigen - immunology (135) 135
t-lymphocytes, regulatory - immunology (135) 135
cancer therapies (134) 134
chemotherapy (132) 132
research (132) 132
antineoplastic combined chemotherapy protocols - therapeutic use (127) 127
clinical trials as topic (127) 127
immune response (127) 127
medicine, research & experimental (127) 127
research & experimental medicine (127) 127
chemical and pharmacologic phenomena (125) 125
health aspects (124) 124
molecular targeted therapy (124) 124
antibodies (122) 122
monoclonal antibodies (121) 121
analysis (118) 118
melanoma - pathology (117) 117
cytokines (116) 116
medical research (111) 111
t cell receptors (111) 111
cd8-positive t-lymphocytes - immunology (109) 109
cell biology (109) 109
melanoma - therapy (106) 106
ligands (105) 105
antibodies, monoclonal - administration & dosage (104) 104
cell line, tumor (104) 104
skin neoplasms - drug therapy (102) 102
disease models, animal (101) 101
immunoglobulins (101) 101
antineoplastic agents - pharmacology (99) 99
review (99) 99
lymphocyte activation - immunology (98) 98
mice, inbred balb c (97) 97
ctla-4 antigen - genetics (95) 95
combined modality therapy (94) 94
proteins (94) 94
drug therapy (93) 93
pd-l1 (92) 92
programmed cell death 1 receptor - metabolism (92) 92
nivolumab (90) 90
antibodies, monoclonal - immunology (87) 87
biomarkers (87) 87
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1640) 1640
French (21) 21
German (14) 14
Czech (10) 10
Japanese (6) 6
Danish (3) 3
Chinese (2) 2
Hungarian (2) 2
Hebrew (1) 1
Italian (1) 1
Polish (1) 1
Russian (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PloS one, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, pp. e83139 - e83139
... synapse between T cells and antigen-presenting cells (APCs). What remains incompletely understood is how CD28 leads to the activation of effector T cells (Teff... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | B7-1 Antigen - antagonists & inhibitors | Cell Communication - immunology | B7-2 Antigen - genetics | B7-1 Antigen - genetics | Dendritic Cells - immunology | Humans | Molecular Targeted Therapy | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Cytotoxic - drug effects | CD28 Antigens - genetics | Protein Binding - drug effects | CD28 Antigens - antagonists & inhibitors | T-Lymphocytes, Regulatory - cytology | Dendritic Cells - drug effects | B7-2 Antigen - immunology | T-Lymphocytes, Cytotoxic - immunology | Gene Expression | B7-2 Antigen - antagonists & inhibitors | B7-1 Antigen - immunology | Antibodies, Monoclonal - pharmacology | CTLA-4 Antigen - genetics | CD28 Antigens - immunology | CTLA-4 Antigen - immunology | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Cell Movement - drug effects | T-Lymphocytes, Regulatory - drug effects | B7-H1 Antigen - antagonists & inhibitors | Lymphocyte Activation - drug effects | Cell Communication - drug effects | Dendritic Cells - cytology | CTLA-4 Antigen - antagonists & inhibitors | T-Lymphocytes, Cytotoxic - cytology | Viral antibodies | Antibodies | Antigens | B cells | T cells | Motility | Transplants & implants | Calcium | Blocking antibodies | Homeostasis | Effector cells | Immunological synapses | Lymphocytes T | Kinases | CD28 antigen | T-cell receptor | CTLA-4 protein | Cell activation | Immunology | Lymphocytes | Dwell time | Cell cycle | Cytokines | Immunoregulation | CD80 antigen | T cell receptors | Costimulator | Microscopy | Antigen-presenting cells | PD-L1 protein | Ligands | Cell migration | Synapses | Apoptosis | Index Medicus | Life Sciences | Human health and pathology
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 03/2017, Volume 74, pp. 55 - 72
Abstract Recent success in cancer immunotherapy (anti-CTLA-4, anti-PD1/PD-L1) has confirmed the hypothesis that the immune system can control many cancers... 
Hematology, Oncology and Palliative Medicine | Molecular biology | Clinical development | Immuno-oncology | Novel antibodies | Life Sciences & Biomedicine | Oncology | Science & Technology | T-Lymphocyte Subsets - immunology | Immunotherapy - methods | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | B7 Antigens - immunology | Inducible T-Cell Co-Stimulator Protein - agonists | Glucocorticoid-Induced TNFR-Related Protein - drug effects | OX40 Ligand - agonists | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | Lymphocyte Activation - immunology | Neoplasms - therapy | Immunity, Cellular - physiology | Killer Cells, Natural - immunology | Tumor Necrosis Factor Receptor Superfamily, Member 9 - agonists | Cytokines - immunology | T-Lymphocytes, Cytotoxic - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | CD40 Antigens - agonists | Antigens, CD - drug effects | B7 Antigens - antagonists & inhibitors | B-Lymphocytes - immunology | Neoplasms - immunology | Major Histocompatibility Complex - immunology | CTLA-4 Antigen - antagonists & inhibitors | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Receptors, KIR - antagonists & inhibitors | Drugs | Chemotherapy | Cell death | Immunotherapy | Monoclonal antibodies | Control systems | T cells | Cancer | CD40 antigen | Toxicity | Clinical trials | Lymphocytes T | CD223 antigen | Drug delivery | Drug resistance | Drug development | Molecules | CTLA-4 protein | Cell activation | New combinations | Immune system | Medical research | Immune response | CD137 antigen | Caspase | Patients | Caspase-8 | Gene amplification | Major histocompatibility complex | Exhaustion | Brake presses | Mutation | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 02/2016, Volume 54, pp. 139 - 148
Journal Article
Journal of hematology and oncology, ISSN 1756-8722, 05/2017, Volume 10, Issue 1, pp. 103 - 103
... antigens and kill the cancer cells. The whole process is elegantly explained by Chen and Mellman with the concept of the cancer-immunity cycle, which consists... 
PD-L1 | PD-L2 | Hematologic malignancies | CTLA-4 | Immune checkpoint | PD-1 | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Tumor Escape - drug effects | B7-H1 Antigen - physiology | Humans | Hepatitis A Virus Cellular Receptor 2 - physiology | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Clinical Trials as Topic | Antigens, CD - drug effects | Programmed Cell Death 1 Receptor - physiology | Molecular Targeted Therapy | Antigen-Presenting Cells - immunology | Biomarkers, Tumor | Patient Selection | Antineoplastic Agents, Immunological - adverse effects | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | B7-H1 Antigen - antagonists & inhibitors | Multicenter Studies as Topic | Antineoplastic Agents, Immunological - therapeutic use | Lymphocyte Activation - drug effects | Hematologic Neoplasms - drug therapy | Antigens, CD - physiology | CTLA-4 Antigen - antagonists & inhibitors | CTLA-4 Antigen - physiology | PD-1 protein | Lung cancer | Clinical trials | Recovery of function | Cytotoxicity | Biology | CD223 antigen | Myeloma | Myelodysplastic syndrome | Proteins | CTLA-4 protein | Immunology | Lymphocytes | Immunotherapy | Janus kinase 2 | Antigens | Immunoglobulins | Immune response | Myeloid leukemia | Melanoma | Immunosurveillance | T cell receptors | Lymphoma | PD-L1 protein | Biomarkers | Ligands | Lymphomas | Acute myeloid leukemia | Binding sites | Hodgkin's disease | Apoptosis | Index Medicus
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2017, Volume 58, pp. 22 - 33
Highlights • Immune checkpoint inhibitors (ICI) have achieved a great success in adult cancers. • There is growing interest in ICI for pediatric malignancies.... 
Hematology, Oncology and Palliative Medicin